VedaBio

CRISPR Cascade™ achieves clinical validation and a clear FDA clearance pathway within 24 months, and the Siemens Healthineers strategic agreement converts into a meaningful commercial licensing deal worth $50M+, catalyzing a Series B close at ~$250M valuation. After ~20% dilution from the new round, current common equity holders realize approximately 150% upside — still well within the Series A bull cap of +400%.

Platform development progresses on schedule but regulatory timelines extend beyond the 2-year horizon, limiting commercial traction; the Siemens partnership generates milestone payments but no recurring revenue. A Series B closes at ~$150M valuation — a modest 1.25–1.5x step-up from an estimated ~$110M post-money — and after ~20% dilution from new shares, current equity holders net roughly 18% upside with no near-term liquidity event.

A clinical or technical setback undermines the amplification-free detection thesis, or the Siemens partnership fails to convert into commercial terms, forcing a flat or down round by mid-2027. With $40.1M in liquidation preferences senior to common stock and a dilutive emergency raise, employee common equity loses approximately 80% of its stated grant-date value.